Fresenius SE Long Term Debt 2016-2025 | FSNUY
Fresenius SE long term debt from 2016 to 2025. Long term debt can be defined as the sum of all long term debt fields.
- Fresenius SE long term debt for the quarter ending December 31, 2025 was $10.432B, a 1.72% increase year-over-year.
- Fresenius SE long term debt for 2025 was $10.432B, a 1.72% increase from 2024.
- Fresenius SE long term debt for 2024 was $10.255B, a 17.3% decline from 2023.
- Fresenius SE long term debt for 2023 was $12.4B, a 38.01% decline from 2022.
|
Fresenius SE Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2025 | $10,432 |
| 2024 | $10,255 |
| 2023 | $12,400 |
| 2022 | $20,004 |
| 2021 | $19,669 |
| 2020 | $19,215 |
| 2019 | $18,036 |
| 2018 | $16,581 |
| 2017 | $18,246 |
| 2016 | $14,212 |
| 2015 | $15,109 |
|
Fresenius SE Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-12-31 | $10,432 |
| 2025-09-30 | $11,143 |
| 2025-06-30 | $10,570 |
| 2025-03-31 | $10,629 |
| 2024-12-31 | $10,255 |
| 2024-09-30 | $12,056 |
| 2024-06-30 | $11,811 |
| 2024-03-31 | $11,868 |
| 2023-12-31 | $12,400 |
| 2023-09-30 | $11,860 |
| 2023-06-30 | $19,188 |
| 2023-03-31 | $21,251 |
| 2022-12-31 | $20,004 |
| 2022-09-30 | $19,249 |
| 2022-06-30 | $19,859 |
| 2022-03-31 | $19,687 |
| 2021-12-31 | $19,669 |
| 2021-09-30 | $21,359 |
| 2021-06-30 | $21,930 |
| 2021-03-31 | $17,857 |
| 2020-12-31 | $19,215 |
| 2020-09-30 | $20,834 |
| 2020-06-30 | $17,829 |
| 2020-03-31 | $17,021 |
| 2019-12-31 | $18,036 |
| 2019-09-30 | $17,979 |
| 2019-06-30 | $17,774 |
| 2019-03-31 | $17,590 |
| 2018-12-31 | $16,581 |
| 2018-09-30 | $16,286 |
| 2018-06-30 | $17,884 |
| 2018-03-31 | $19,380 |
| 2017-12-31 | $18,246 |
| 2017-09-30 | $19,384 |
| 2017-06-30 | $18,829 |
| 2017-03-31 | $18,934 |
| 2016-12-31 | $14,212 |
| 2016-09-30 | $13,731 |
| 2016-06-30 | $14,819 |
| 2016-03-31 | $14,433 |
| 2015-12-31 | $15,109 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $29.514B | $25.873B |
| Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |